Table 2.
Relationship between HPV pyrosequencing status and clinical parameters
| Parameter | HPV Neg/wk (n = 46) | HPV Strong (n = 36) | p value |
|---|---|---|---|
| Age | |||
| Mean (±SE) | 61 (± 2.1) | 55 (± 1.6) | 0.03 |
| <60 | 20 (24.4%) | 26 (31.7%) | 0.01 |
| ≥60 | 26 (31.7%) | 10 (12.2%) | |
| Gender | |||
| Male | 36 (43.9%) | 33 (40.2%) | 0.13 |
| Female | 10 (12.2%) | 3 (3.7%) | |
| Site | |||
| Oropharynx | 16 (19.5%) | 33 (40.2%) | <0.0001 |
| Oral cavity | 12 (14.6%) | 1 (1.2%) | |
| Larynx | 6 (7.3%) | 1 (1.2%) | |
| Hypopharynx | 6 (7.3%) | 1 (1.2%) | |
| Nasopharynx | 3 (3.7%) | 0 (1.2%) | |
| Other* | 3 (3.7%) | 0 | |
| Cigarette pack-year | |||
| Mean (±SE) | 40.0 (± 5.5) | 28.3 (± 4.5) | 0.12 |
| Differentiation | |||
| Well | 8 (9.8%) | 4 (4.9%) | 0.52 |
| Moderate | 29 (35.4%) | 26 (31.7%) | |
| Poor | 9 (11.0%) | 6 (7.3%) | |
| T-classification | |||
| 0–2 | 20 (24.4%) | 22 (26.8%) | 0.12 |
| 3–4 | 26 (31.7%) | 14 (17.1%) | |
| N-classification | |||
| 0–1 | 10 (12.2%) | 1 (1.2%) | 0.008 |
| 2 | 23 (28.0%) | 29 (35.4%) | |
| 3 | 13 (15.9%) | 6 (7.3%) | |
| Stage | |||
| II–III | 8 (9.8%) | 1 (1.2%) | 0.07 |
| IV | 38 (46.3%) | 35 (42.7%) | |
| Treatment | |||
| Nonsurgical therapy† | 31 (37.8%) | 33 (40.2%) | 0.01 |
| Surgical therapy‡ | 15 (18.3%) | 3 (3.7%) | |
| Hemoglobin | |||
| Mean (±SE) | 13.5 (±0.28) | 14.3 (±0.23) | 0.06 |
| ≤12 g/dL | 13 (15.9%) | 3 (3.7%) | 0.05 |
| >12 g/dL | 33 (40.2%) | 31 (37.8%) | |
| Unknown | 0 | 2 (2.4%) |
Abbreviations: CRT = chemoradiation; HPV = human papillomavirus; Neg = negative; OP = Oropharynx; RT = radiation; S = surgery; SE = standard error; Wk = weak.
*
Others included two paranasal sinus and one unknown squamous cell carcinomas.
†
Primary nonsurgical therapy included radiation alone (3 patients) and chemoradiation (61 patients).
‡
Primary surgical therapy included surgery alone (2 patients), surgery + postoperative radiation (9 patients), and surgery + postoperative chemoradiation (7 patients)